Table 2.
Outcome of the 36 children with philadelphia chromosome-positive acute lymphoblastic leukemia as a function of early characteristics
| No patients | No CR (%) | p | 5 yr-EFS | p | 5 yr-OS | p | |
|---|---|---|---|---|---|---|---|
| Whole cohort | N = 36 | 26 (72%) | 33.3 ± 7.9 | 47.2 ± 8.3 | |||
| Inclusion period | |||||||
| < July, 1996 | 15 | 9 (60%) | 20 ± 10 | 33 ± 12 | |||
| > July, 1996 | 21 | 17 (81%) | 0.26 | 43 ± 11 | 0.13 | 57 ± 11 | 0.31 |
| Age (years) | |||||||
| <10 | 23 | 20 (87%) | 48 ± 10 | 61 ± 10 | |||
| ≥ 10 | 13 | 6 (46%) | 0.018 | 15 ± 10 | 0.01 | 23 ± 12 | 0.006 |
| WBC (/mm3) | |||||||
| <50,000 | 21 | 17 (81%) | 33 ± 10 | ||||
| ≥ 50,000 | 15 | 9 (60%) | 0.26 | 33 ± 12 | 0.54 | 0.91 | |
| <100,000 | 26 | 22 (85%) | 42 ± 10 | 58 ± 10 | |||
| ≥ 100,000 | 10 | 4 (40%) | 0.014 | 10 ± 9 | 0.003 | 20 ± 13 | 0.03 |
| Response to steroid (+3 drug intra-thecal injection) at D8 | |||||||
| poor (≥ 1000 blasts/mm3) | 5 | 2 (40%) | 20 ± 18 | 20 ± 18 | |||
| good(<1000 blasts/mm3) | 31 | 24 (77%) | 0.12 | 35 ± 9 | 0.33 | 52 ± 9 | 0.19 |
| Response to chemotherapy evaluated on D21 | |||||||
| M1(≤ 5% blasts) | 21 | 20 (95%) | 43 ± 11 | 62 ± 11 | |||
| M2+M3 (>5%–25% and >25% blasts) | 15 | 6 (40%) | 0.0004 | 20 ± 10 | 0.18 | 27 ± 11 | 0.06 |
| Age, D21 response and WBC | |||||||
| Age<10 and D21 M1 and WBC count<100,000 | 14 | 14 (100%) | 57 ± 13 | 79 ± 11 | |||
| Others | 22 | 12 (55%) | 0.003 | 18 ± 8 | 0.002 | 27 ± 9 | 0.003 |
WBC = white blood cell; D = day; Response to steroid is evaluated in peripheral blood on day 8; Response to chemotherapy is evaluated in bone marrow on day 21